8 crispr stocks to watch

Considering investing in crispr stocks? While the best crispr stocks depend on your portfolio and investment goals, we've identified some crispr stocks that are worth keeping an eye on in the gene editing sector. Keep reading to learn more about crispr stocks and how to start investing.

8 popular crispr stocks to watch

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap stocks.

Best stock	1-year return	Market cap	Exchange	Volume	Buy on Questrade
Crispr Therapeutics (CRSP.US)	-9.31% Crispr Therapeutics's 1-year return based on the closing price as of November 7, 2025.	$5.2 billion (USD)	NASDAQ	1,288,700	Buy now
Editas Medicine (EDIT.US)	8.10% Editas Medicine's 1-year return based on the closing price as of November 7, 2025.	$394.7 million (USD)	NASDAQ	2,909,100	Buy now
Regeneron Pharmaceuticals (REGN.US)	22.43% Regeneron Pharmaceuticals's 1-year return based on the closing price as of November 7, 2025.	$84.3 billion (USD)	NASDAQ	527,700	Buy now
Beam Therapeutics Inc (BEAM.US)	18.55% Beam Therapeutics Inc's 1-year return based on the closing price as of November 7, 2025.	$2.8 billion (USD)	NASDAQ	1,434,270	Buy now
Eli Lilly and Company (LLY.US)	53.40% Eli Lilly and Company's 1-year return based on the closing price as of November 7, 2025.	$1.3 trillion (USD)	NYSE	3,638,304	Buy now
Intellia Therapeutics (NTLA.US)	30.99% Intellia Therapeutics's 1-year return based on the closing price as of November 7, 2025.	$1.7 billion (USD)	NASDAQ	4,077,500	Buy now
Caribou Biosciences (CRBU.US)	-78.74% Caribou Biosciences's 1-year return based on the closing price as of November 7, 2025.	$47.2 million (USD)	NASDAQ	1,233,004	Buy now
Vertex Pharmaceuticals (VRTX.US)	34.09% Vertex Pharmaceuticals's 1-year return based on the closing price as of November 7, 2025.	$136.9 billion (USD)	NASDAQ	1,810,265	Buy now

The values in this table are accurate as of the market close on November 2, 2026, or the most recent data available. Volume refers to the number of shares traded during the day.

What to look for when investing in crispr stock

The gene editing industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering crispr stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.

Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.

How to invest in crispr stock

1. Research the gene editing industry. Before investing, learn about the crispr stock sector, its trends and the companies within it. Look at each company's financial health, potential for growth and past performance to identify stocks that fit your investment goals.
2. Choose a stock trading platform. Compare trading fees, access to trading tools and user interface options. We've identified reliable trading platforms to help narrow down your options below or check out the best stock trading apps in Canada to find one that suits your needs.
3. Open and fund your account. Sign up with your personal details and link a bank account or funding method to deposit money before you start trading.
4. Select the crispr stock(s) to buy. Search by company name or ticker symbol, like CRSP or EDIT. Compare key metrics such as market cap, price history and earnings per share to pick the best stock for your strategy.
5. Buy the stock and monitor performance. Place your order to buy the stock and track its performance over time. Consider setting alerts, signing up for industry newsletters or using platform research tools to stay up to date on market changes.

Our top picks for where to buy crispr stocks

Are crispr stocks a good investment?

While it's possible to turn a profit investing in crispr stocks, keep in mind that—like any investment—crispr stocks are not immune to risk. These stocks are subject to fluctuating conditions both in the market and in the gene editing industry, so carefully vet your picks before you invest.

What are the best crispr stocks?

A lot of factors go into picking the best crispr stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong crispr stock investment for one person might not be suitable for another.

That said, we rounded up this list of popular crispr stocks in or related to the gene editing industry to help narrow down your options:

• Crispr Therapeutics (CRSP)
• Editas Medicine (EDIT)
• Regeneron Pharmaceuticals (REGN)
• Beam Therapeutics Inc (BEAM)
• Eli Lilly and Company (LLY)
• Intellia Therapeutics (NTLA)
• Caribou Biosciences (CRBU)
• Vertex Pharmaceuticals (VRTX)

Keep in mind that this is not a "best" list or a recommendation. It highlights some crispr stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.

We've outlined detailed company and stock performance details for each crispr stock below. Keep reading to decide if any of these companies are the right investment for you.

---

Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.

Closing stock price	$49.99
Market Capitalization The total market value of Crispr Therapeutics's outstanding shares	$5.2 billion
Gross profit (TTM)	$-461,800,992
Revenue (TTM)	$13.4 million
Earnings per share (TTM)	-$4.74
52-week stock price range	$44.12 – $64.74

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 2, 2026.

---

Editas Medicine (EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.

Closing stock price	$2.67
Market Capitalization The total market value of Editas Medicine's outstanding shares	$394.7 million
Gross profit (TTM)	$-37,954,000
Profit margin	-157.32%
Revenue (TTM)	$47 million
Earnings per share (TTM)	-$0.65
52-week stock price range	$1.66 – $3.94

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on October 29, 2026.

---

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.

Closing stock price	$805.02
Market Capitalization The total market value of Regeneron Pharmaceuticals's outstanding shares	$84.3 billion
Gross profit (TTM)	$6.9 billion
Profit margin	27.87%
Revenue (TTM)	$15.5 billion
Earnings per share (TTM)	$40.44
52-week stock price range	$590.83 – $859.34

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on October 22, 2026.

---

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.

The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.

Closing stock price	$26.33
Market Capitalization The total market value of Beam Therapeutics Inc's outstanding shares	$2.8 billion
Gross profit (TTM)	$-252,628,992
Profit margin	-55.45%
Revenue (TTM)	$156 million
Earnings per share (TTM)	-$0.68
52-week stock price range	$20.23 – $38.26

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 2, 2026.

---

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.

Closing stock price	$1,417.99
Market Capitalization The total market value of Eli Lilly and Company's outstanding shares	$1.3 trillion
Gross profit (TTM)	$72.3 billion
Profit margin	31.90%
Revenue (TTM)	$86.5 billion
Earnings per share (TTM)	$30.67
52-week stock price range	$847.83 – $1,449.68

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 3, 2026.

---

Intellia Therapeutics (NTLA)

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing.

The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.

Closing stock price	$12.47
Market Capitalization The total market value of Intellia Therapeutics's outstanding shares	$1.7 billion
Gross profit (TTM)	$-222,816,000
Revenue (TTM)	$59.5 million
Earnings per share (TTM)	-$3.35
52-week stock price range	$7.95 – $18.48

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on October 29, 2026.

---

Caribou Biosciences (CRBU)

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.

The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

Closing stock price	$0.44
Market Capitalization The total market value of Caribou Biosciences's outstanding shares	$47.2 million
Gross profit (TTM)	$-73,818,000
Revenue (TTM)	$10 million
Earnings per share (TTM)	-$1.12
52-week stock price range	$0.41 – $2.49

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 3, 2026.

---

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.

Closing stock price	$549.04
Market Capitalization The total market value of Vertex Pharmaceuticals's outstanding shares	$136.9 billion
Gross profit (TTM)	$6.9 billion
Profit margin	35.00%
Revenue (TTM)	$12.6 billion
Earnings per share (TTM)	$17.17
52-week stock price range	$403.16 – $560.25

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 3, 2026.

Compare trading platforms to buy CRISPR stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Bottom line

If you're considering adding crispr stocks to your portfolio, make sure you thoroughly look into any companies before investing to help mitigate risk. We've compiled a list of crispr stocks to help narrow down your options. Then choose a legitimate stock trading platform to start investing. After that it comes down to monitoring the gene editing industry to know when to buy, sell or hold. How to buy stocks in Canada

Frequently asked questions about crispr stocks

• What are crispr stocks?

  Crispr stocks are shares of companies that either directly work in the crispr sector or operate within related industries. Investors interested in buying crispr stocks may be looking to take advantage of market trends or lock in investments for the long haul.

• What is the top crispr stock to buy in 2026?

  Unfortunately, it's almost impossible to choose a single "top" crispr stock to invest in due to factors like market fluctuations, company management and shifting economic trends. These can all change—sometimes overnight—how a stock performs. It's best to do your own research to decide which companies fit within your risk tolerance. Reviewing a company's financial reports and past stock performance can help you decide if it's worth investing in.

• Where can I find information and regular updates about the gene editing industry?

  You can keep track of the latest gene editing news and updates by signing up for financial newsletters, visiting financial news sites, reading company investor relations pages and using market research platforms. Many online brokerages also offer sector reports, stock screeners and alerts to help you track movements in your stock performance or updates in or related to the gene editing industry.

Check these other commodities and investment sectors

If you're thinking about diversifying your portfolio and investing in sectors beyond crispr stocks, here are some others you can consider:

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.